Completed PHASE1 INTERVENTIONAL 2-arm NCT00846131

Y-90 Alone or With Sorafenib for Pre-Transplant Hepatocellular Carcinoma

A Single-Center Proof of Concept Pilot Study to Evaluate the Safety, Efficacy, and Tolerability of Sorafenib Combined With Therasphere in Subjects With Hepatocellular Carcinoma Awaiting Liver Transplantation.

Sponsor: National Cancer Institute (NCI)

Conditions Hepatocellular Carcinoma

Interventions Sorafenib Yttrium-90 (Y-90)

Updated 5 times since 2017 Last updated: Sep 13, 2016 Started: Feb 28, 2009 Primary completion: Jul 31, 2015 Completion: Sep 30, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00846131, this PHASE1 trial focuses on Hepatocellular Carcinoma and remains completed. Sponsored by National Cancer Institute (NCI), it has been updated 5 times since 2009, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Feb 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)
Northwestern University

Data source: Northwestern University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Chicago, United States